Access to technology and foundational math proficiency among students: empirical evidence from India - Nature

Todd Hughes has a complicated relationship with Danish. The 64-year-old can read a Danish novel without much trouble. But put him in a room full of native speakers, and the plot thickens. His Danish dilemma illustrates the difference between sounding fluent and actually becoming proficient. Technology can help someone learn vocabulary, practice skills, or move smoothly through a translated exchange. But proficiency is about what someone can actually do across reading, writing, listening, and speaking—and communicating proficiently still requires navigating another person.

by Kristin Bien, WSBT22OperationEducationReporterWed, October 21, 2026 at 4:30 AMA teacher writes on the white board during class at Wa-Nee Community Schools. The district is celebrating its high ILEARN proficiency in ELA and math (WSBT 22)Wa-Nee Community School students are outperforming nearly every nearby district and most of the state on the ILEARN. Tonight, Operation Education is investigating what is behind the high ILEARN proficiency rates in Wa-Nee Community SchoolsThe 2026 results for the ILEARN 3-8 assessment taken by students in April were released by the Indiana Department of Education in September. It shows as a district, 62.2% of Wa-Nee third through eighth graders are proficient in ELA and 69.7% are proficient in mathematics. RELATED: Operation Education: Compare spring ILEARN results of Indiana students"School by school, all three of our elementary schools and our middle school have really performed very well. They've all made gains in every area," said Wa-Nee Community Schools Assistant Superintendent Gretchen Thomas. When compared with other districts in Elkhart and St.

News|Articles|October 24, 2026 Baseline and on-treatment circulating tumor DNA (ctDNA) features, including TP53 mutations and methylation-based tumor fraction, were associated with early progression or prolonged progression-free survival (PFS) with first-line lorlatinib (Lorbrena) in patients with ALK-positive advanced non–small cell lung cancer (NSCLC), in exploratory analyses of the phase 3 CROWN trial (NCT03052608) presented at the 2026 European Society for Medical Oncology (ESMO) Congress.1Compared with long-term responders, who were progression free at 84 months (n = 30), early progressors, who had a PFS event within 12 months (n = 22), had a higher median number of altered genes at baseline (10 vs 6), a higher median blood-based tumor mutation burden (7.7 vs 5.1), and more frequent TP53 mutations (50% vs 17%). In the lorlatinib arm, the 7-year PFS rate was 65.0% (95% CI, 54.5%-77.4%) in patients with TP53 wild-type disease (n = 73) vs 40.8% (95% CI, 27.3%-61.1%) in those with TP53-mutated disease (n = 43; HR, 0.48; 95% CI, 0.268-0.857); median PFS was not reached (NR) vs 51.6 months (95% CI, 16.4-NR), respectively.

CML treatment has transformed long-term survival, allowing many patients receiving effective TKI therapy to achieve a life expectancy approaching that of the general population. Molecular response milestones guide personalized treatment decisions, helping clinicians assess treatment effectiveness, recognize inadequate responses, and adjust therapy when necessary.